Pharvaris N.V. Ordinary Shares (PHVS)
Pharvaris N.V. Ordinary Shares (PHVS) is listed on Nasdaq, where it has traded since February 5, 2021.
- Listed On
- Nasdaq
- Listed Since
- February 5, 2021
- Employees
- 129
- Market Cap
- $2.3B
About Pharvaris N.V. Ordinary Shares
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 123 institutions reported holding PHVS, with 64.5 million shares worth $2.2 billion in aggregate. The largest reported holder was FMR, with 6.6 million shares worth $227.0 million. Of the 5 largest holders listed below, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 6,565,272 | $227M | Added 4.47% |
| General Atlantic | 6,550,757 | $227M | Reduced 18.43% |
| Foresite Capital Management IV | 4,778,581 | $165M | Unchanged |
| Venbio Partners | 4,643,430 | $161M | Added 0.09% |
| Viking Global Investors | 3,653,310 | $126M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is PHVS?
Pharvaris N.V. Ordinary Shares (PHVS) is listed on Nasdaq, where it has traded since February 5, 2021.
Who are the largest institutional holders of PHVS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of PHVS were FMR, General Atlantic and Foresite Capital Management IV.
How many institutions own PHVS?
123 institutions reported a position in PHVS for the quarter ended June 30, 2026, worth $2.2 billion in total.
Did institutions buy or sell PHVS last quarter?
Of the 5 largest reported holders, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for PHVS.
Every reported institutional holder, plus insider and congressional trades in PHVS, on SentiSense.